Abstract: Belumosudil (KD025), marketed as REZUROCK, is an orally active, selective inhibitor of Rho-associated coiled-coil-containing protein kinase 2 (ROCK2). Initially developed and approved for the treatment of chronic graft-versus-host disease (cGVHD) after the failure of prior systemic therapies, belumosudil has garnered significant attention for its dual mechanism of action: restoring immune homeostasis and directly inhibiting fibrotic processes. By downregulating pro-inflammatory Th17 and T follicular helper (Tfh) cells while enhancing regulatory T (Treg) cells, and simultaneously blocking pro-fibrotic gene transcription and myofibroblast activation, belumosudil addresses both the inflammatory and fibrotic hallmarks of complex autoimmune and fibrotic disorders. Given its potent anti-fibrotic capabilities, the research direction for belumosudil has expanded into systemic sclerosis, a disease characterized by widespread skin and internal organ fibrosis. This review synthesizes the current literature on belumosudil, detailing its pharmacological activity, molecular mechanisms, structure-activity relationship, current limitations, and future perspectives, with a specific focus on its translational potential for systemic sclerosis.
1. Introduction
Systemic sclerosis is a complex, immune-mediated rheumatic disease characterized by vasculopathy, immune dysregulation, and progressive fibrosis of the skin and internal organs. The development of nonreversible fibrosis is associated with substantial morbidity and mortality, highlighting a critical unmet need for targeted anti-fibrotic therapies. Belumosudil (KD025), an orally active small molecule developed by Kadmon Pharmaceuticals, has emerged as a promising therapeutic agent in this domain [1]. Belumosudil is a selective inhibitor of Rho-associated coiled-coil-containing protein kinase 2 (ROCK2) [2].
In July 2021, belumosudil received its first approval in the United States for the treatment of adult and pediatric patients aged 12 years and older with chronic graft-versus-host disease (cGVHD) who have failed at least two prior lines of systemic therapy [1] [7]. The pathological hallmark of cGVHD—much like systemic sclerosis—is driven by an imbalance in effector T cells and regulatory T cells, culminating in aberrant tissue repair and significant, irreversible fibrosis [2]. Because belumosudil directly targets both the inflammatory and fibrotic pathways, its clinical development has actively expanded into systemic sclerosis. Currently, patients with diffuse cutaneous systemic sclerosis are being recruited for two major Phase II clinical trials (NCT04680975 and NCT03919799) to evaluate the efficacy and safety of belumosudil in this specific patient population [1].
2. Pharmacological Activity
The pharmacological efficacy of belumosudil has been robustly demonstrated in clinical trials, most notably the Phase II ROCKstar trial (NCT03640481), which evaluated its use in heavily pretreated patients with fibrotic and inflammatory disease manifestations [1] [7]. Belumosudil administered at 200 mg once or twice daily achieved an overall response rate (ORR) of 74% and 77%, respectively [1] [8]. Notably, the drug demonstrated high efficacy in highly fibrotic tissues, achieving response rates of 71% to 75% in joints and fascia, 55% to 69% in the gastrointestinal tract and mouth, and significant responses in the skin and lungs [4] [6] [9]. Furthermore, treatment enabled 65% of patients to reduce their corticosteroid doses, and many experienced clinically meaningful improvements in symptom burden [1] [7].
Pharmacokinetically, belumosudil exhibits dose-proportional increases in maximum plasma concentration (Cmax) and area under the curve (AUC). Following oral administration, the median time to Cmax at steady state is 1.26 to 2.53 hours, with a mean bioavailability of 64% [1]. The drug has a geometric mean volume of distribution of 184 L and is highly protein-bound (99.9% to human serum albumin). It is primarily metabolized by the CYP3A4 enzyme, with a mean elimination half-life of 19 hours and a clearance rate of 9.83 L/h [1]. Mild to moderate renal impairment, age, sex, and body weight do not have a clinically meaningful effect on its pharmacokinetics [1].
3. Molecular Mechanism of Action
The therapeutic potential of belumosudil in systemic sclerosis is rooted in its unique, dual mechanism of action that simultaneously addresses immune dysregulation and aberrant tissue fibrosis through the selective inhibition of ROCK2 [2].
Immunomodulatory Effects: ROCK2 signaling is critical for regulating T-cell-mediated immune responses. Belumosudil restores immune homeostasis by downregulating the phosphorylation of signal transducer and activator of transcription 3 (STAT3) and upregulating the phosphorylation of STAT5 [1] [2]. The inhibition of the JAK2/STAT3 complex decreases the activation of transcription factors such as IRF4, RORγt, and Bcl6. This triggers a significant downregulation of pro-inflammatory T helper 17 (Th17) and T follicular helper (Tfh) cells, which are responsible for secreting pro-fibrotic cytokines like IL-17 and IL-21 [2] [5]. Concurrently, STAT5 upregulation shifts the balance toward a regulatory T (Treg) cell phenotype, reducing chronic inflammation and autoantibody production [1] [2].
Anti-Fibrotic Effects: Independent of its immune effects, belumosudil directly inhibits fibrotic processes, making it highly relevant for systemic sclerosis. ROCK2 activation normally promotes the polymerization of G-actin to F-actin, leading to the development of contractile stress fibers. Belumosudil inhibits this actin polymerization [2]. Furthermore, it suppresses pro-fibrotic gene expression and transforming growth factor-beta (TGF-β) signaling. By inhibiting myocardin-related transcription factor-mediated transcription, belumosudil blocks the differentiation of fibroblasts into myofibroblasts, thereby halting excessive collagen deposition, alpha-smooth muscle actin (α-SMA) expression, and connective tissue growth factor (CTGF) production [1] [2]. In preclinical models, this has been shown to remodel the actin cytoskeleton, strengthen endothelial barrier integrity, and reverse existing fibrosis in the skin and lungs [1] [2].
4. Structure-Activity Relationship (SAR)
Belumosudil is chemically designated as 2-[3-[4-(1H-indazol-5-ylamino)quinazolin-2-yl]phenoxy]-N-propan-2-ylacetamide (also known as belumosudil mesylate, KD-025, or SLX-2119) [1]. Structurally, it belongs to the classes of acetamides, indazoles, phenyl ethers, and quinazolines [1]. The structural conformation of belumosudil confers a high degree of selectivity for the ROCK2 isoform over ROCK1. Pharmacodynamic profiling reveals that belumosudil inhibits ROCK2 with a half-maximal inhibitory concentration (IC50) of approximately 100 nM, whereas its IC50 for ROCK1 is 3 µM [1]. This selective inhibition is crucial, as it allows for the targeted modulation of immune and fibrotic pathways mediated by ROCK2 without inducing the systemic toxicities that might arise from pan-ROCK inhibition.
5. Current Limitations
While belumosudil is generally well-tolerated, it is associated with several limitations and adverse events (AEs). In clinical trials, the most frequent AEs (incidence ≥ 20%) included infections (53%), asthenia (46%), nausea (42%), diarrhea (35%), dyspnea (33%), cough (30%), edema (27%), hemorrhage (23%), musculoskeletal pain (22%), and hypertension (21%) [1] [7]. Grade 3 or 4 AEs included severe infections, decreased lymphocytes, increased γ-glutamyl transferase (GGT), and decreased phosphate [1]. Some meta-analyses have noted that while highly effective, belumosudil can present a challenging safety profile regarding grade 3-5 adverse events in heavily pretreated populations [3].
Drug-drug interactions present another limitation. Because belumosudil is a substrate of CYP3A4 and P-glycoprotein, coadministration with strong CYP3A inducers (e.g., rifampin) or proton pump inhibitors (e.g., rabeprazole, omeprazole) significantly decreases its Cmax and AUC, potentially reducing efficacy and necessitating a dose increase to 200 mg twice daily [1]. Conversely, belumosudil inhibits CYP1A2, CYP2C19, CYP2D6, UGT1A1, and UGT1A9, which can alter the exposure of co-administered medications [1]. Additionally, based on its mechanism of action and animal studies, belumosudil may cause fetal harm and is not recommended during pregnancy or breastfeeding [1].
6. Future Perspectives
The future of belumosudil is heavily tied to its ongoing evaluation in systemic sclerosis. The Phase II trials (NCT04680975 and NCT03919799) investigating its efficacy in diffuse cutaneous systemic sclerosis will provide critical data on whether the potent anti-fibrotic and immunomodulatory effects observed in cGVHD can be successfully translated to primary autoimmune fibrotic diseases [1].
Future research directions also include the identification of reliable biomarkers to predict patient response. Biomarkers such as IL-21, IL-17, Tfh cell counts, ST2, and soluble B-cell activating factor (sBAFF) are being explored to refine risk stratification and personalize treatment regimens [2] [5]. Furthermore, combination therapies are an active area of investigation. Combining belumosudil with other targeted agents (such as B-cell inhibitors or JAK inhibitors like ruxolitinib) may yield synergistic effects, overcoming potential drug resistance and providing deeper fibrotic reversal [2] [5]. Finally, pharmaceutical advancements, such as the development of a novel oral suspension formulation, aim to improve drug accessibility and compliance for patients suffering from severe esophageal or gastrointestinal fibrosis who experience dysphagia [2].
